New prospects for antipsychotic treatment - The role of the kynurenine pathway;Nowe perspektywy w leczeniu przeciwpsychotycznym - Znaczenie szlaku kynureninowego

Psychiatria Polska

Volumn 48, Issue 6, 2014, Pages 1167-1177

  Karakula Juchnowicz, Hanna ^a   Flis, Marta ^b   Szymona, Kinga ^c   Kuczyńska, Maryla ^d   Stelmach, Ewa ^b   Kowal Popczak, Agnieszka ^e  

^a Zak ad Neuropsychiatrii Klinicznej Katedry i Kliniki Psychiatrii UM w Lublinie   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c Poradnia Zdrowia Psychicznego   (Poland)

^d Naukowe przy Katedrze   (Poland)

^e UM w Lublinie   (Poland)

Author keywords

3 hydroxykynurenine; Antipsychotics; Kynurenic acid

Indexed keywords

3 HYDROXYKYNURENINE; KYNURENIC ACID; KYNURENINE; NEUROLEPTIC AGENT; TRYPTOPHAN;

ARTICLE; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HUMAN; MANIA; MENTAL DISEASE; PREFRONTAL CORTEX; SCHIZOPHRENIA; ANIMAL; DRUG EFFECTS; METABOLISM; NERVE TRACT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; KYNURENIC ACID; KYNURENINE; NEURAL PATHWAYS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84920168982     PISSN: 00332674     EISSN: 23915854     Source Type: Journal    
DOI: 10.12740/PP/25520     Document Type: Article

References (50)

1. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 1993; 45(3): 309-379.
2. Stone TW. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog. Neurobiol. 2001; 64(2): 185-218.
3. Andiné P, Lehmann A, Ellrén K, Wennberg E, Kjellmer I, Nielsen T. i wsp. The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. Neurosci. Lett. 1988; 90(1-2): 208-212.
4. Baran H, Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer's disease. J. Neural. Transm. 1999; 106(2): 165-181.
5. Beal MF, Matson WR, Story E, Milbury P, Ryan EA, Ogawa T. i wsp. Kynurenic acid concentration are reduced in Huntington's disease cerebral cortex. J. Neurol. Sci. 1992; 108(1): 80-87.
6. Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J. Neurochem. 1990; 55(4): 1327-1339.
7. Connick JH, Carla V, Moroni F, Stone TW. Increase in kynurenic acid in Huntington's disease motor cortex. J. Neurochem. 1989; 52(3): 985-987.
8. Wu HQ, Schwarcz R. Seizure activity causes elevation of endogenous extracellular kynurenic acid in the rat brain. Brain Res. Bull. 1996; 39(3): 155-162.
9. Olsson SK, Samuelsson M, Saetre P, Lindström L, Jönsson EG, Nordin C. i wsp. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J. Psychiatry Neurosci. 2010; 35(3): 195-199.
10. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 2007; 98(1-2): 143-151.
11. Olajossy M. Poziom kwasu kynureninowego w surowicy krwi chorych na depresję leczonych elektrycznie. Rozprawa habilitacyjna. Lublin: Uniwersytet Medyczny; 2010.
12. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G. Kynurenic acid levels are elevated in the cerbrospinal fluid of patients with schizophrenia. Neurosci. Lett. 2001; 313(1-2): 96-98.
13. Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpé S. i wsp. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav. Immun. 2011; 25(8): 1576-1581.
14. Myint AM, Kim YK, Verkerk R, Park SH, Scharpé S, Steinbusch HW. i wsp. Tryptophan breakdown pathway in bipolar mania. J. Affect. Disord. 2007; 102(1-3): 65-72.
15. Gellért L, Varga D, Ruszka M, Toldi J, Farkas T, Szatmári I. i wsp. Behavioural studies with a newly developed neuroprotective KYNA-amide. J. Neural. Transm. 2012; 119(2): 165-172.
16. Salter M, Hazelwood R, Pogson CI, Iyer R, Madge DJ. The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. Biochem. Pharmacol. 1995; 49(10): 1435-1442.
17. Pellicciari R, Rizzo RC, Costantino G, Marinozzi M, Amori L, Guidetti P. i wsp. Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)-benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. ChemMedChem 2006; 1(5): 528-531.
18. Carpenedo R, Pittaluga A, Cozzi A, Attucci S, Galli A, Raiteri M. i wsp. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci. 2001; 13(11): 2141-2147.
19. Moroni F, Russi P, Lombardi G, Beni M, Carla V. Presence of kynurenic acid in the mammalian brain. J. Neurochem. 1988; 51(1): 177-180.
20. Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO Jr, Schwarcz R. Identification and quantification of kynurenic acid in human brain tissue. Brain Res. 1988; 454(1-2): 164-169.
21. Cannazza G, Chiarugi A, Parenti C, Zanoli P, Baraldi M. Changes in kynurenic, anthranilic, and quinolinic acid concentration in rat brain tissue during development. Neurochem. Res. 2001; 26(5): 511-514.
22. Rossi F, Schwarcz R, Rizzi M. Curiosity to kill the KAT (kynurenine aminotransferase): structural insights into brain kynurenic acid synthesis. Curr. Opin. Struct. Biol. 2008; 18(6): 748-755.
23. Turski W, Sekundy A. Kwas kynureninowy - rola w fizjologii i patologii os̈rodkowego układu nerwowego. Farm. Pol. 2000; 56(9): 449-453.
24. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 1991; 56(6): 2007-2017.
25. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP. Human microglia convert L-tryptophan into the neurotoxin quinolic acid. Biochem. J. 1996; 320(2); 595-597.
26. Okuda S, Nishiyama N, Saito H, Katsuki H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc. Natl. Acad. Sci. USA 1996; 93(22): 12553-12558.
27. Okuda S, Nishiyama N, Saito H, Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem. 1998; 70(1): 299-307.
28. Rios C, Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 1991; 16(10): 1339-1343.
29. Saito K, Heyes MP. Kynurenine pathway enzymes in brain. Properties of enzymes and regulation of quinolinic acid synthesis. Adv. Exp. Med. Biol. 1996; 398: 485-492.
30. Carlsson A, Lindqvist M. Effects of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharm. Toxicol. 1963; 20(2): 140-144.
31. Karakula H, Flis M, Szymona K, Studenna M. Kwas kynureninowy a objawy pozytywne w schizofrenii. Curr. Probl. Psychiatry 2011; 12(4): 516-519.
32. Müller N. Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development. Expert Opin. Ther. Targets 2008; 12(12): 1497-1507.
33. Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol. Behav. 2007; 92(1-2): 203-209.
34. Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G. Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci. 2008; 83(5-6): 170-175.
35. Poeggler B, Rassoulpour A, Wu HQ, Guidetti P, Roberts RC, Schwarcz R. Dopamine receptor activations reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity. Neuroscience 2007; 148(1): 188-197.
36. Erhardt S, Engberg G. Increased phasic activity of dopaminergic neurons in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynuretic acid. Acta Physiol. Scand. 2002; 175(1): 45-53.
37. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 2001; 50(7): 521-530.
38. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J. Neural Transm. 2006: 113(10): 1355-1365.
39. Colangelo V, Di Grezia R, Passarelli F, Musicco M, Pontieri FE, Orzi F. Differential effects of acute administration of clozapine or haloperidol on local cerebral glucose utilization in the rat. Brain Res. 1997; 768(1): 273-278.
40. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005; 10(1): 79-104.
41. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull. 2007; 33(3): 797-804.
42. Foster AC, Vezzani A, French ED, Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 1984; 48(3): 273-278.
43. Condray R, Dougherty GG Jr, Keshavan MS, Reddy RD, Haas GL, Montrose DM. i wsp. 3-hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol. 2011; 14(6): 756-767.
44. Lee M, Jayathilake K, Dai J, Meltzer HY. Decreased plasma tryptophan and tryptophan/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: relationship to plasma cortisol concentration. Psychiatry Res. 2011; 185(3): 328-333.
45. Wonodi I, Schwarz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr. Bull. 2010; 36(2): 211-218.
46. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 2012; 13(7): 465-477.
47. Wu HQ, Pellicciari R, Schwarcz R. Bidirectional regulation of extracellular dopamine by endogenous kynurenic acid in the rat medical prefrontal cortex. Abstr. Soc. Neurosci. 2006; 32: 624.3.
48. Zmarowski A, Wu HQ, Brooks JM, Potter MC, Pellicciari R, Schwarcz R. i wsp. Astrocytederived kynurenic acid modulates basal and evoked cortical acetylcholine release . Eur. J. Neurosci. 2009; 29(3): 529-538.
49. Wu HQ, Pereira EF, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R. The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J. Mol. Neurosci. 2010; 40(1-2): 204-210.
50. Strzelecki D, Kropiwnicki P, Rabe-Jablońska J. Augmentacja leczenia przeciwpsychotycznego glicynĄ może zmniejszaæ nasilenie objawów depresyjnych oraz pozapiramidowych u chorych na schizofrenię - wyniki wstępnego 10-tygodniowego badania otwartego. Psychiatr. Pol. 2013; 47(4): 609-620.